C&EN · Jun 2026
Profile of PostEra’s AI-first drug discovery model, its cofounders, partnerships with Pfizer/Amgen/NIH, open-science roots, internal women’s health pipeline, and plans to raise a Series B.
Company research
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Overview
PostEra is an AI-first biotechnology company that uses its Proton platform for medicinal chemistry to accelerate small-molecule drug discovery and development. The company runs both an internal pipeline (notably women’s health and fertility) and partnered co-discovery programs with pharma.
Primary product
Proton, an end-to-end machine learning platform for medicinal chemistry
Founded
2019
Headquarters
Boston, Massachusetts, United States
Team size
11-50
Industry
Biotechnology Research
Sub-industry
AI drug discovery / medicinal chemistry / techbio
Offices
Boston, Massachusetts, United States
Cambridge, Massachusetts, United States (mentioned in primary-source news / team context)
Business model
partnered drug discovery collaborations
internal drug pipeline development
AI/medicinal chemistry platform licensing or services via strategic collaborations
Funding
Stage
Series A
Total raised
$26.5M
Latest round
Series A · Jan 2022
Latest amount
$24M
Grant
May 2022 · National Institutes of Health
Jan 2022 · Clermont Group
Seed Round
Mar 2020
Corporate Round
Oct 2019
People & investors
Leadership
CEO & Co-Founder
Co-Founder & Chief Scientific Officer
Matthew Robinson
Co-Founder
Rachael Springer
People Operations Lead
Adam Morra
Machine Learning Lead
James Gayvert
Technical Lead
Nikki Simpson
Lead Investigator, in vivo Pharmacology
Thomas Vargo
Lead Investigator
Courtney Tiffany
Lead Investigator, Clinical Development Operations
Tony S.
Head of Machine Learning
Work & culture
Primary-source materials emphasize a research-heavy, collaborative culture of drug hunters, researchers, and engineers, with a strong focus on scientific rigor and AI not being a black box.
Product & market
Pricing
Primarily B2B strategic collaboration / partnered discovery contracts; exact pricing is not public.
Differentiators
- —Proton platform focused on medicinal chemistry and the Design-Make-Test cycle
- —Synthesis-aware / AI-first drug discovery approach
- —Combines internal pipeline with partnered co-discovery
- —Publicly cited large-scale collaborations with Pfizer, Amgen, and NIH
- —Open-science heritage via COVID Moonshot
Technology
Python
Django
Kubernetes
PostgreSQL
microservices
Unix
Microsoft Office
QuickBooks
Customers
Pfizer
Amgen
National Institutes of Health (NIH)
Competitors
Recursion
Exscientia
Insitro
Generate:Biomedicines
Schrödinger
Scale & contact
Estimated revenue
Not publicly disclosed; likely driven mainly by partnerships and milestones, but no reliable public revenue estimate found.
Estimated monthly visits
1.4K
Traffic estimate as of Jun 2026
Latest news
C&EN · Jan 2025
Independent reporting on the Pfizer/PostEra expansion, the ADC focus, and the company’s note that NIH AViDD funding was nearing exhaustion.
PRNewswire · Jan 2025
Official announcement of a new ADC collaboration with Pfizer, a $12M upfront payment, and an expanded collaboration value up to $610M.
PostEra · Jan 2025
Company news page states the Pfizer collaboration expanded to $610M.
PostEra · Mar 2024
Primary-source update on Pfizer AI Lab progress and target nomination.